Tripelennamine
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Metabolism | Hepatic hydroxylation and glucuronidation |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.910 |
| Chemical and physical data | |
| Formula | C16H21N3 |
| Molar mass | 255.358 g/mol g·mol−1 |
Tripelennamine (INN, also known as pyribenzamine) is a first generation pyridine antipruritic and antihistamine in the ethylenediamine class. It can be used in the treatment of asthma, hay fever, rhinitus and urticaria but is now less common as it has been replaced by newer antihistamines. This drug is sold in 50 mg tablets, which are usually green in colour. Tripellenamine is marketed by Novartis under the trade name Pyribenzamine.
Tripelennamine was first synthesized by Carl Djerassi, working in the laboratory of Charles Huttrer at Ciba, shortly after Djerassi got his B.S. It was his first patent.
Side effects
Tripelennamine is mildly sedating. Other side effects can include gastrointestinal irritation, dry mouth, nausea, and dizziness.
Recreational use
Tripelennamine is sometimes abused recreationally in combination with the opiate pentazocine ("T's & Blues"), morphine ("Blue Velvet") and narcotic cough syrups. It is dangerous to combine an opiate with a sedating antihistamine via injection, although the use of antihistamines (usually by mouth) to reduce opioid requirements for pain relief is a well-known practice, which is done under medical supervision with tripelennamine, as well as hydroxyzine, cyclizine, promethazine, diphenhydramine, phenindamine, orphenadrine, meclizine, chlorpheniramine, cyproheptadine and others; this method is doubly useful when used with opioids which release a great deal of histamine when administered and therefore cause itching, redness of skin and other histamine-related effects.